FDC Ltd
FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]
- Market Cap ₹ 4,928 Cr.
- Current Price ₹ 297
- High / Low ₹ 318 / 225
- Stock P/E 25.4
- Book Value ₹ 119
- Dividend Yield 0.00 %
- ROCE 13.1 %
- ROE 9.84 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.7% over past five years.
- Company has a low return on equity of 12.6% over last 3 years.
- Working capital days have increased from 79.8 days to 143 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
710 | 772 | 845 | 888 | 994 | 1,013 | 1,074 | 1,089 | 1,341 | 1,331 | 1,525 | 1,784 | |
545 | 591 | 638 | 690 | 765 | 769 | 841 | 860 | 1,038 | 997 | 1,271 | 1,533 | |
Operating Profit | 165 | 181 | 207 | 199 | 229 | 243 | 233 | 229 | 304 | 334 | 254 | 251 |
OPM % | 23% | 23% | 24% | 22% | 23% | 24% | 22% | 21% | 23% | 25% | 17% | 14% |
27 | 46 | 39 | 46 | 39 | 44 | 45 | 42 | 57 | 95 | 76 | 50 | |
Interest | 1 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 4 |
Depreciation | 18 | 28 | 25 | 39 | 34 | 35 | 35 | 33 | 37 | 38 | 37 | 39 |
Profit before tax | 172 | 198 | 218 | 204 | 232 | 252 | 241 | 237 | 320 | 388 | 289 | 258 |
Tax % | 22% | 22% | 38% | 27% | 27% | 25% | 28% | 28% | 25% | 22% | 25% | 25% |
Net Profit | 134 | 155 | 135 | 148 | 169 | 189 | 174 | 170 | 240 | 301 | 216 | 194 |
EPS in Rs | 7.33 | 8.49 | 7.61 | 8.33 | 9.48 | 10.60 | 9.95 | 9.74 | 14.03 | 17.85 | 12.82 | 11.70 |
Dividend Payout % | 27% | 26% | 30% | 27% | 24% | 21% | 0% | 0% | 6% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 11% |
3 Years: | 10% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | 2% |
3 Years: | -6% |
TTM: | -8% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 6% |
3 Years: | 4% |
1 Year: | 22% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 13% |
3 Years: | 13% |
Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 17 | |
Reserves | 677 | 766 | 827 | 919 | 1,065 | 1,252 | 1,259 | 1,428 | 1,530 | 1,717 | 1,940 | 1,965 |
4 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 15 | 15 | 32 | 28 | |
163 | 179 | 211 | 210 | 182 | 197 | 228 | 194 | 250 | 207 | 281 | 333 | |
Total Liabilities | 863 | 966 | 1,059 | 1,148 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 |
293 | 289 | 284 | 393 | 675 | 678 | 674 | 682 | 674 | 689 | 705 | 700 | |
CWIP | 11 | 7 | 18 | 29 | 20 | 6 | 13 | 12 | 24 | 19 | 105 | 198 |
Investments | 340 | 416 | 417 | 489 | 325 | 491 | 471 | 585 | 665 | 790 | 886 | 806 |
219 | 254 | 340 | 237 | 246 | 293 | 348 | 360 | 451 | 458 | 575 | 640 | |
Total Assets | 863 | 966 | 1,059 | 1,148 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
144 | 150 | 150 | 128 | 174 | 154 | 150 | 112 | 250 | 207 | 162 | 155 | |
-108 | -107 | -55 | -89 | -73 | -144 | 21 | -121 | -98 | -77 | -145 | 11 | |
-58 | -63 | -75 | -48 | -97 | 0 | -169 | -0 | -142 | -129 | -10 | -180 | |
Net Cash Flow | -22 | -20 | 19 | -9 | 4 | 11 | 1 | -8 | 10 | 1 | 7 | -14 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 22 | 20 | 26 | 25 | 23 | 27 | 28 | 29 | 34 | 30 | 20 | 25 |
Inventory Days | 132 | 117 | 116 | 132 | 134 | 148 | 166 | 184 | 180 | 189 | 210 | 183 |
Days Payable | 74 | 72 | 90 | 94 | 84 | 81 | 101 | 82 | 101 | 68 | 94 | 99 |
Cash Conversion Cycle | 79 | 66 | 51 | 64 | 72 | 94 | 93 | 131 | 113 | 152 | 135 | 109 |
Working Capital Days | 25 | 24 | 2 | 11 | 21 | 23 | 29 | 45 | 41 | 50 | 47 | 143 |
ROCE % | 25% | 23% | 25% | 21% | 22% | 21% | 19% | 17% | 21% | 22% | 15% | 13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
26 May - Press Release issued in relation to the Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year ended March 31, 2023.
- Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (LODR) Regulations, 2015. 25 May
-
Announcement under Regulation 30 (LODR)-Change in Directorate
25 May - Appointment of Mr. Vijay Nautamlal Bhatt (DIN: 00751001), as an Additional Non-Executive Independent Director of the Company for a period of 5 (Five) years with …
- Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31, 2023 25 May
- Board Meeting Outcome for Outcome Of Board Meeting Held On May 25, 2023 25 May
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Dec 2021TranscriptPPT
-
Jun 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
May 2016TranscriptNotesPPT
Revenue Breakup
Anti-infective medicines contribute 42% of revenues, followed by gastro intestinal 24%, vitamins/ minerals 7%, ophthalmology 6%, cardiac 7%, dermatology 4% and others 11%.[1]